Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NAN Stock Summary
Top 10 Correlated ETFs
NAN
In the News

Alternative Small-Cap ETFs In Place Of iShares IJR Offering
iShares Core S&P Small-Cap ETF is a leader in the Small-Cap S&P index-based ETFs universe. With the focus on large-cap stocks, the small-cap universe is not on every investor's buy list.

Alternative Mid-Cap ETFs In Place Of IJH
iShares Core S&P MidCap ETF is the best known and largest pure Mid-Cap ETF available but is it the best choice for this market segment? Many investors are so focused on Large-Cap stocks, they do not have much exposure to the ones outside the S&P 500 universe.

The Reopening Killed The V-Shaped Recovery
This is a weekly series focused on analyzing the previous week’s economic data releases. The objective is to concentrate on leading indicators of economic activ
New York re-open will require 'regional control room', Cuomo says
New York Governor Andrew Cuomo says a "regional control room" will be needed to keep track of COVID-19 infections in order to re-open New York's businesses."We want to re-open, but we want
New York, East Coast states extend lockdown to May 15
While some officials have floated the idea of starting to re-open the economy around May, that won't including the Northeast states, which are currently the U.S. epicenter of the coravirus pandemic.Ne
New COVID-19 hospitalization numbers continue to fall in New York
New York Governor Andrew Cuomo reports 200 net new hospitalizations for COVID-19 in the state yesterday, the lowest number since the crisis began.Also declining are intensive-care admissions and intub
Moody's revises New York state outlook to negative
The state of New York's GO rating is affirmed by Moody's at Aa1 while its outlook is revised to negative from stable.The outlook change reflects Moody's expectation that the crisis will have substanti

Nuveen New York Dividend Advntg Mncpl Fd (NYSE:NAN) Trading Up 4.1%
Shares of Nuveen New York Dividend Advntg Mncpl Fd (NYSE:NAN) traded up 4.1% on Thursday . The stock traded as high as $12.38 and last traded at $12.84, 88,343 shares were traded during trading. An increase of 22% from the average session volume of 72,386 shares. The stock had previously closed at $12.33. The firm […]

Nuveen New York Dividend Advntg Mncpl Fd (NYSE:NAN) Shares Sold by Guggenheim Capital LLC
Guggenheim Capital LLC lowered its stake in shares of Nuveen New York Dividend Advntg Mncpl Fd (NYSE:NAN) by 10.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 335,374 shares of the financial services provider’s stock after selling 39,879 shares during […]

Citigroup Inc. Grows Stake in Nuveen New York Dividend Advntg Mncpl Fd (NYSE:NAN)
Citigroup Inc. grew its holdings in Nuveen New York Dividend Advntg Mncpl Fd (NYSE:NAN) by 41.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 23,778 shares of the financial services provider’s stock after buying an additional 7,025 shares during the quarter. Citigroup Inc.’s holdings […]
NAN Financial details
NAN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-02-28
Metric | History | 2019-02-28 | 2020-02-29 | 2021-02-28 | 2022-02-28 | 2023-02-28 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.66 | 1.97 | -0.05 | -0.02 | -1.84 | |
Net income per share | 0.62 | 1.93 | -0.08 | -0.06 | -1.88 | |
Operating cash flow per share | -0.17 | 0.58 | 0.71 | 0.74 | 1.2 | |
Free cash flow per share | -0.17 | 0.58 | 0.71 | 0.74 | 1.2 | |
Cash per share | -0.02 | 0 | 0 | 0 | 0 | |
Book value per share | 14.74 | 16.06 | 14.21 | 14.96 | 12.25 | |
Tangible book value per share | 14.74 | 16.06 | 14.21 | 14.96 | 12.25 | |
Share holders equity per share | 14.74 | 16.06 | 14.21 | 14.96 | 12.25 | |
Interest debt per share | 0.22 | 0.22 | 0.22 | 0.1 | 0.23 | |
Market cap | 395.57M | 444.66M | 467.99M | 399.68M | 327.02M | |
Enterprise value | 396.86M | 445.79M | 472.83M | 400.92M | 328.33M | |
P/E ratio | 20.76 | 7.48 | -175.63 | -220.17 | -5.64 | |
Price to sales ratio | 19.5 | 7.34 | -293.07 | -546.49 | -5.75 | |
POCF ratio | -76.79 | 24.77 | 19.79 | 17.84 | 8.85 | |
PFCF ratio | -76.79 | 24.77 | 19.79 | 17.84 | 8.85 | |
P/B Ratio | 0.87 | 0.9 | 0.99 | 0.88 | 0.87 | |
PTB ratio | 0.87 | 0.9 | 0.99 | 0.88 | 0.87 | |
EV to sales | 19.57 | 7.36 | -296.1 | -548.18 | -5.78 | |
Enterprise value over EBITDA | -75.57 | 12.58 | -18.68 | -18.79 | -4.13 | |
EV to operating cash flow | -77.04 | 24.84 | 19.99 | 17.89 | 8.88 | |
EV to free cash flow | -77.04 | 24.84 | 19.99 | 17.89 | 8.88 | |
Earnings yield | 0.05 | 0.13 | -0.01 | 0 | -0.18 | |
Free cash flow yield | -0.01 | 0.04 | 0.05 | 0.06 | 0.11 | |
Debt to equity | 0 | 0 | 0.01 | 0 | 0 | |
Debt to assets | 0 | 0 | 0.01 | 0 | 0 | |
Net debt to EBITDA | -0.25 | 0.03 | -0.19 | -0.06 | -0.02 | |
Current ratio | 0.22 | 0.31 | 0.85 | 0.55 | 0.27 | |
Interest coverage | 4.4 | 4.31 | 8.89 | 11.13 | 3.77 | |
Income quality | -0.27 | 0.3 | -8.88 | -12.34 | -0.64 | |
Dividend Yield | 0.05 | 0.04 | 0.04 | 0.05 | 0.05 | |
Payout ratio | 0.95 | 0.3 | -7.09 | -10.36 | -0.29 | |
Sales general and administrative to revenue | 0.06 | 0.02 | -0.65 | -1.45 | -0.02 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 14.34 | 26.41 | 5.06 | 4.49 | 22.76 | |
ROIC | 0.07 | 0.02 | -0.4 | -0.46 | -0.02 | |
Return on tangible assets | 0.03 | 0.08 | 0 | 0 | -0.09 | |
Graham Net | -8.69 | -8.56 | -7.41 | -8.55 | -7.72 | |
Working capital | -29.48M | -25.92M | -4.83M | -17.99M | -21.1M | |
Tangible asset value | 453.18M | 494.88M | 473.21M | 452.69M | 378.02M | |
Net current asset value | -264.34M | -260.91M | -239.88M | -253.1M | -236.27M | |
Invested capital | 0 | 0 | 0.01 | 0 | 0 | |
Average receivables | 12.37M | 9.97M | 19.76M | 25.16M | 15.13M | |
Average payables | 6.31M | 1.61M | 1.54M | 7.13M | 7.03M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 150.56 | 69.82 | -6.39K | -11.17K | -50.55 | |
Days payables outstanding | -63.63 | 18.25 | -18.7 | -180.82 | -5.81 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 2.42 | 5.23 | -0.06 | -0.03 | -7.22 | |
Payables turnover | -5.74 | 20 | -19.52 | -2.02 | -62.85 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.04 | 0.12 | -0.01 | 0 | -0.15 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-02-28 for Q4
Metric | History | 2022-02-28 | 2022-05-31 | 2022-08-31 | 2022-11-30 | 2023-02-28 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.2 | 0.21 | 0.21 | 0.22 | 0.22 | |
Net income per share | -0.36 | -0.88 | -0.88 | -0.06 | -0.06 | |
Operating cash flow per share | 0.14 | -0.14 | -0.14 | 0.74 | 0.74 | |
Free cash flow per share | 0.14 | -0.14 | -0.14 | 0.74 | 0.74 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 14.67 | -1.49 | 12.63 | -1.87 | 12.25 | |
Tangible book value per share | 14.67 | 12.63 | 12.63 | 12.25 | 12.25 | |
Share holders equity per share | 14.67 | -1.49 | 12.63 | -1.87 | 12.25 | |
Interest debt per share | 0.04 | 7.62 | 0.62 | 6.97 | 0.04 | |
Market cap | 407.55M | 371.14M | 353.56M | 338.13M | 327.03M | |
Enterprise value | 408.78M | 371.14M | 372.67M | 338.13M | 328.34M | |
P/E ratio | -9.07 | -3.43 | -3.27 | -43.87 | -42.43 | |
Price to sales ratio | 65.98 | 56.86 | 54.16 | 50.05 | 48.41 | |
POCF ratio | 94.96 | -83.4 | -79.45 | 14.75 | 14.26 | |
PFCF ratio | 94.96 | -83.4 | -79.45 | 14.75 | 14.26 | |
P/B Ratio | 0.9 | -8.05 | 0.91 | -5.87 | 0.87 | |
PTB ratio | 0.9 | -8.05 | 0.91 | -5.87 | 0.87 | |
EV to sales | 66.18 | 56.86 | 57.09 | 50.05 | 48.6 | |
Enterprise value over EBITDA | -25.46 | -11.5 | -11.54 | -45.23 | -43.92 | |
EV to operating cash flow | 95.25 | -83.4 | -83.74 | 14.75 | 14.32 | |
EV to free cash flow | 95.25 | -83.4 | -83.74 | 14.75 | 14.32 | |
Earnings yield | -0.03 | -0.07 | -0.08 | -0.01 | -0.01 | |
Free cash flow yield | 0.01 | -0.01 | -0.01 | 0.07 | 0.07 | |
Debt to equity | 0 | -5.1 | 0.05 | -3.73 | 0 | |
Debt to assets | 0 | 0.35 | 0.03 | 0.35 | 0 | |
Net debt to EBITDA | -0.08 | 0 | -0.59 | 0 | -0.18 | |
Current ratio | 0.55 | 0.39 | 0.39 | 0.27 | 0.27 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | -0.38 | 0.16 | 0.16 | -11.9 | -11.9 | |
Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Payout ratio | -0.41 | -0.17 | -0.17 | -2.09 | -2.09 | |
Sales general and administrative to revenue | 0.22 | 0.2 | 0.2 | 0.18 | 0.18 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 10.96 | 5.43 | 15.78 | 1.62 | 4.15 | |
ROIC | 0 | -0.01 | 0 | -0.1 | -0.04 | |
Return on tangible assets | -0.02 | -0.04 | -0.04 | 0 | 0 | |
Graham Net | -8.39 | -9.2 | -8.74 | -7.91 | -7.72 | |
Working capital | -17.99M | -29.59M | -29.59M | -21.1M | -21.1M | |
Tangible asset value | 452.69M | 389.62M | 389.62M | 378.02M | 378.02M | |
Net current asset value | -253.1M | -264.72M | -264.72M | -236.27M | -236.27M | |
Invested capital | 0 | -5.1 | 0.05 | -3.73 | 0 | |
Average receivables | 11.19M | 11.19M | 9.58M | 9.58M | 3.94M | |
Average payables | 12.03M | 7.21M | 2.47M | 1.63M | 663.51K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 326.2 | 0 | 264.18 | 0 | 104.86 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.28 | 0 | 0.34 | 0 | 0.86 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.02 | 0.59 | -0.07 | 0.03 | -0.01 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
NAN Frequently Asked Questions
What is Nuveen New York Quality Municipal Income Fund stock symbol ?
Nuveen New York Quality Municipal Income Fund is a US stock , located in Chicago of Il and trading under the symbol NAN
What is Nuveen New York Quality Municipal Income Fund stock quote today ?
Nuveen New York Quality Municipal Income Fund stock price is $10.58 today.
Is Nuveen New York Quality Municipal Income Fund stock public?
Yes, Nuveen New York Quality Municipal Income Fund is a publicly traded company.